Rapid Identification of Novel Allosteric PRC2 Inhibitors.Read, J.A., Tart, J., Rawlins, P.B., Gregson, C., Jones, K., Gao, N., Zhu, X., Tomlinson, R., Code, E., Cheung, T., Chen, H., Kawatkar, S.P., Bloecher, A., Bagal, S., O'Donovan, D.H., Robinson, J.
(2019) ACS Chem Biol 14: 2134-2140
- PubMed: 31525019
- DOI: https://doi.org/10.1021/acschembio.9b00468
- Primary Citation of Related Structures:
- PubMed Abstract:
Enhancer of zeste homologue 2 (EZH2), the catalytic subunit of polycomb repressive complex 2 (PRC2), regulates chromatin state and gene expression by methylating histone H3 lysine 27. EZH2 is overexpressed or mutated in various hematological malignancies and solid cancers. Our previous efforts to identify inhibitors of PRC2 methyltransferase activity by high-throughput screening (HTS) resulted in large numbers of false positives and thus a significant hit deconvolution challenge. More recently, others have reported compounds that bind to another PRC2 core subunit, EED, and allosterically inhibit EZH2 activity. This mechanism is particularly appealing as it appears to retain potency in cell lines that have acquired resistance to orthosteric EZH2 inhibition. By designing a fluorescence polarization probe based on the reported EED binding compounds, we were able to quickly and cleanly re-triage our previously challenging HTS hit list and identify novel allosteric PRC2 inhibitors.
Discovery Biology, Discovery Sciences , R&D, AstraZeneca , Cambridge , CB4 0WG U.K.